Gul Kanyilmaz1, Meryem Aktan2, Mehmet Koc2, Hikmettin Demir2, Lütfi Saltuk Demir3. 1. Department of Radiation Oncology, Necmettin Erbakan University Meram Medicine School, Akyokus Mevkii, 42090, Konya, Turkey. drgulgun@yahoo.com. 2. Department of Radiation Oncology, Necmettin Erbakan University Meram Medicine School, Akyokus Mevkii, 42090, Konya, Turkey. 3. Department of Public Health and Biostatistics, Necmettin Erbakan University Meram Medicine School, Konya, Turkey.
Abstract
AIMS: To evaluate the incidental dose to the internal mammary chain (IMC) in patients treated with three-dimensional conformal radiotherapy, to estimate the predictors affecting the magnitude of IMC receiving dose and to determine the predictive role of clinical parameters on survival. MATERIALS AND METHODS: Between 2009 and 2015, 348 patients undergoing RT for breast cancer were retrospectively analyzed. All patients underwent our department's routine procedure for breast cancer. The internal mammary lymph nodes were contoured according to Radiation Therapy Oncology Group (RTOG) concensus. Based on each patient's dose-volume histograms, the mean doses (D mean) to internal mammary gland were analyzed. Overall survival and disease-free survival were also evaluated. RESULTS: The median follow-up time was 38 (range 3-80) months. The D mean to IMC was 32.8 Gy and the dose delivered to IMC showed a greater coverage in modified radical mastectomy (MRM) group compared with breast conserving surgery (34.6 vs 26.7 Gy). The T-stage of tumor and the N-stage of tumor affected the incidental dose to IMC. The tumor size, the number of involved lymph nodes, the percentage of involved lymph nodes, hormonal status, advanced T-stage and advanced N-stage were the prognostic factors that affect survival. CONCLUSION: The IMC received meaningful incidental irradiation dose when treated with two opposite tangential fields and ipsilateral supraclavicular fossa with a single anterior field. The real effect of incidental dose on survival and the hypothesis about the benefit of incidental irradiation of IMC should be examined in clinical studies.
AIMS: To evaluate the incidental dose to the internal mammary chain (IMC) in patients treated with three-dimensional conformal radiotherapy, to estimate the predictors affecting the magnitude of IMC receiving dose and to determine the predictive role of clinical parameters on survival. MATERIALS AND METHODS: Between 2009 and 2015, 348 patients undergoing RT for breast cancer were retrospectively analyzed. All patients underwent our department's routine procedure for breast cancer. The internal mammary lymph nodes were contoured according to Radiation Therapy Oncology Group (RTOG) concensus. Based on each patient's dose-volume histograms, the mean doses (D mean) to internal mammary gland were analyzed. Overall survival and disease-free survival were also evaluated. RESULTS: The median follow-up time was 38 (range 3-80) months. The D mean to IMC was 32.8 Gy and the dose delivered to IMC showed a greater coverage in modified radical mastectomy (MRM) group compared with breast conserving surgery (34.6 vs 26.7 Gy). The T-stage of tumor and the N-stage of tumor affected the incidental dose to IMC. The tumor size, the number of involved lymph nodes, the percentage of involved lymph nodes, hormonal status, advanced T-stage and advanced N-stage were the prognostic factors that affect survival. CONCLUSION: The IMC received meaningful incidental irradiation dose when treated with two opposite tangential fields and ipsilateral supraclavicular fossa with a single anterior field. The real effect of incidental dose on survival and the hypothesis about the benefit of incidental irradiation of IMC should be examined in clinical studies.
Authors: R Arriagada; M G Lê; H Mouriesse; F Fontaine; J Dewar; F Rochard; M Spielmann; J Lacour; M Tubiana; D Sarrazin Journal: Radiother Oncol Date: 1988-03 Impact factor: 6.280
Authors: M Clarke; R Collins; S Darby; C Davies; P Elphinstone; V Evans; J Godwin; R Gray; C Hicks; S James; E MacKinnon; P McGale; T McHugh; R Peto; C Taylor; Y Wang Journal: Lancet Date: 2005-12-17 Impact factor: 79.321
Authors: M Overgaard; M B Jensen; J Overgaard; P S Hansen; C Rose; M Andersson; C Kamby; M Kjaer; C C Gadeberg; B B Rasmussen; M Blichert-Toft; H T Mouridsen Journal: Lancet Date: 1999-05-15 Impact factor: 79.321
Authors: M Overgaard; P S Hansen; J Overgaard; C Rose; M Andersson; F Bach; M Kjaer; C C Gadeberg; H T Mouridsen; M B Jensen; K Zedeler Journal: N Engl J Med Date: 1997-10-02 Impact factor: 91.245
Authors: B Fowble; A Hanlon; G Freedman; N Nicolaou; J Hoffman; E Sigurdson; M Boraas; M Torosian; L Goldstein Journal: Int J Radiat Oncol Biol Phys Date: 2000-07-01 Impact factor: 7.038
Authors: Philip M Poortmans; Sandra Collette; Carine Kirkove; Erik Van Limbergen; Volker Budach; Henk Struikmans; Laurence Collette; Alain Fourquet; Philippe Maingon; Mariacarla Valli; Karin De Winter; Simone Marnitz; Isabelle Barillot; Luciano Scandolaro; Ernest Vonk; Carla Rodenhuis; Hugo Marsiglia; Nicola Weidner; Geertjan van Tienhoven; Christoph Glanzmann; Abraham Kuten; Rodrigo Arriagada; Harry Bartelink; Walter Van den Bogaert Journal: N Engl J Med Date: 2015-07-23 Impact factor: 91.245
Authors: Susanne H Estourgie; Omgo E Nieweg; Renato A Valdés Olmos; Emiel J Th Rutgers; Bin B R Kroon Journal: Ann Surg Date: 2004-02 Impact factor: 12.969